Oral Anticoagulation Analysis

Superior Essays
Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, has been increased in cancer patients, adversely affecting their prognosis. Low-molecular-weight heparins are recommended as efficacious and safe anticoagulation treatment in cancer patients. However, in clinical practice, oncologists prefer oral anticoagulation, especially if long-term or extended treatment is necessary. The novel oral anticoagulants have recently emerged as an alternative to the standard therapy owing to the ease of administration, predictable anticoagulation effect without the need for laboratory monitoring, and few drug interactions. Currently, the preliminary data showed that these new agents are effective and safe for the management of cancer-associated …show more content…
NOACs can be given with fixed dose regimens without routine coagulation monitoring because of the specific anticoagulant activities (Figure 1), relatively fast onset/offset of actions, and little food or drug interactions. Their efficacy and safety for atrial fibrillation (AF) management in the general population have been proven to be non-inferior to warfarin in various trials (Dogliotti et al., 2013; Larsen et al., 2016; Ruff et al., 2014), and adoption of these agents into clinical practice is growing. A cohort study of over 60,000 AF patients showed that NOAC therapy is replacing warfarin for the VTE management (Patel et al., 2015) and is expanding the indications into mechanical heart valves, heart failure, and coronary artery disease (Yeh et al., 2015). However, these new agents are not popular among oncologists, at least not yet, because of the relatively limited data in the VTE treatment for cancer patients and less familiarity with the agents (Sardar et al., 2015; Wharin and Tagalakis, …show more content…
A recent subset-analyses of cancer patients in NOAC trials have shown non-inferiority to standard therapy consisting of enoxaparin followed by dose-adjusted warfarin (Agnelli et al., 2015; Prins et al., 2014; Raskob et al., 2016; Schulman et al., 2015). Several systemic reviews and meta-analyses of clinical trial data also revealed some evidence for similar efficacy and safety between NOACs and the standard therapy (Hulle et al., 2014; Sardar et al., 2015; Vedovati et al., 2015). However, the extent of the disease or the status of cancer treatment was not described in detail and may affect the outcome of anticoagulation therapy. In addition, these results should be interpreted with caution because of the enrollment of only a small proportion of cancer patients, different definition of active cancer as well as various inclusion criteria for cancer patients (patients with cancer history and patients with new onset of

Related Documents

  • Improved Essays

    Patient Afib Case Study

    • 1191 Words
    • 5 Pages

    Patient Afib is a 58 year old, Caucasian, married male. The patient has been healthy most of his life with no significant health issues until the beginning of this year. One night, in April of 2016, patient Afib began to experience chest pain, shortness of breath, nausea, and vomiting prompting him to visit the emergency room. Subsequent tests revealed that patient Afib had symptomatic atrial fibrillation. Physicians in the ER stated that patient Afib probably had had atrial fibrillation for a while, but it had been exacerbated for an unknown reason.…

    • 1191 Words
    • 5 Pages
    Improved Essays
  • Superior Essays

    Nt1310 Unit 1 Exercise 2

    • 1464 Words
    • 6 Pages

    Circulation. 2011;123(16):1729-1736. doi:10.1161/circulationaha.110.007336. 5. Chiang Y, Chen K, Tsai T, Tsai W. Lowered Cancer Risk With ACE Inhibitors/ARBs: A Population-Based Cohort Study.…

    • 1464 Words
    • 6 Pages
    Superior Essays
  • Improved Essays

    Anticoagulants are blood thinning medications that are used for the treatment and prevention of blood clots. They act mainly by slowing blood clot formation and thus preventing associated complications1.Their approved Food and Drug Administration (FDA) indications include prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and preventing complications associated with atrial fibrillation such as stroke2. For the past years, vitamin-k antagonist (warfarin) has been the primary treatment for a wide range of coagulation related indications3. However, limitations of warfarin have led to the discovery of a new generation of anticoagulants.…

    • 262 Words
    • 2 Pages
    Improved Essays
  • Improved Essays

    Ap Case Study Eliot

    • 946 Words
    • 4 Pages

    Presenting History: Eliot is a 74 year old male presented to the clinic with complaints of frequent nose bleeds and several bruises on the body. He is also complaining of runny nose, cough, head and chest congestion. He has a history of atrial fibrillation and is on warfarin 7mg PO daily. As he experiencing heart burn, he started to take over the counter cimetidine for last three weeks. His physical examination shows, blood pressure 180/95, irregular heart rhythm with a heart rate of 75 and he weighs 95 KG.…

    • 946 Words
    • 4 Pages
    Improved Essays
  • Great Essays

    Warfarin Blood Clots

    • 993 Words
    • 4 Pages

    Question #15: Explain how Warfarin, a popular drug used to treat atrial fibrillation, causes disruptions in human fetal development. Blood clots can form in the body and either be a hindrance or a help. Those that help the body, stop bleeding, so that an excess of blood is not lost all at one time. The blood clots that act as a hindrance to the body can lead to heart attacks, strokes and at times pulmonary embolisms. Warfarin (C19H16O4) is a prescription medication that is used to prevent the harmful blood clots within the body.…

    • 993 Words
    • 4 Pages
    Great Essays
  • Improved Essays

    Rivaroxaban Rivaroxaban is an anticoagulant medication commonly used in the prevention of cerebrovascular accidents and pulmonary embolism in patients suffering from atrial fibrillation. According to a study published in Thrombosis, a peer-reviewed medical journal, rivaroxaban proves to be just as effective at cerebrovascular accident and pulmonary embolism prevention as warfarin (Gómez-Outes et al., 2013). Rivaroxaban has also been approved for the prevention of venous thromboembolism and deep vein thrombosis in individuals who have undergone hip or knee replacement surgery. Rivaroxaban is available as an oral tablet and has a bioavailability of approximately 90%.…

    • 554 Words
    • 3 Pages
    Improved Essays
  • Improved Essays

    Background: Atrial fibrillation (AF) is the most common coronary artery bypass graft (CABG) post-op arrhythmia. This complication can increase the patient’s chances for a longer hospital stay, stroke, or death; resulting in additional healthcare costs. Prescribing statins (3-hydroxy-3-methylglutaryl COA reductase inhibitors) to reduce the risk of postoperative AF (POAF) is well studied, as they provide anti-inflammatory and antioxidant benefits within hours of initiation. However, whether the statin type and/or dose are the origin for these benefits remains unknown; as research is conflicted.…

    • 451 Words
    • 2 Pages
    Improved Essays
  • Great Essays

    Context for Longitudinal Study Using Competing Risk Approaches Despite the fact that the effectiveness of RAAS inhibitors in the primary prevention of AF has been evaluated by several population-based observational studies [23-25], it is not clear whether the RAAS inhibitors remain effective in the reduction of new-onset AF in the older adult hypertensive population when competing risks (e.g. all-cause death) exist. All of these studies simply ignored the existence of the competing risks in their analyses. However, in the presence of the competing risks, it is flawed to examine the effect of the antihypertensive medications on reducing AF risk using the traditional survival analysis approaches such as the Kaplan-Meier methods and the Cox proportional…

    • 1287 Words
    • 6 Pages
    Great Essays
  • Improved Essays

    • If you have severe pulmonary embolism with signs of heart strain, your doctor will likely administer a thrombolytic (tissue plasminogen activator). You may also require an interventional procedure such as thrombectomy. • Other medications frequently used to treat pulmonary embolism include heparin or Lovenox (enoxaparin). • Long term oral blood thinners are often necessary. These include: warfarin (Coumadin), Xarelto (rivaroxaban), Eliquis (apixaban), and Pradaxa (dabigatran).…

    • 1217 Words
    • 5 Pages
    Improved Essays
  • Superior Essays

    For ages now, many Health Care Providers prescribes anticoagulant medicines such as Warfarin also known as Coumadin to prevent clot from forming, developing, and dislodging through the blood vessels. Recently, a newer medications for anticoagulant has been prescribed and now are now popular and more convenient than Warfarin, the drugs are “Xarelto, Eliquis and Pradaxa”, and they are considered to be much safer than Warfarin. (News Medical: Life Sciences and Medicine,…

    • 943 Words
    • 4 Pages
    Superior Essays
  • Improved Essays

    Myeloma Case Studies

    • 230 Words
    • 1 Pages

    Barbara is a 61-year-old female diagnosed with multiple myeloma, IgG Kappa, ISS stage II (C90.0), with ongoing back pain and to have extensive lyic lesions and spinal fractures. Previously, Barbara was treated Pom/Dara/Dex, Vel/Dex, revlimid, autologous transplant, velcade and dexamethasone, but still experienced disease progression. She has symoptomatic progression on Pom/dara/dex with new pain and weakness, along with a marrow that shows t(11:14). Barbara is in need of a more combative treatment. Although Barbara suffers from multiple myeloma not having achieved remission and Venclexta is not FDA approved for this treatment, the FDA does state “it’s labeling is not intended to limit the prescribing of medications of off-label uses, then…

    • 230 Words
    • 1 Pages
    Improved Essays
  • Decent Essays

    Argatroban Research Paper

    • 378 Words
    • 2 Pages

    Some studies which were done on dialysis patients used the same dose in normal renal patients with no additional adverse effects and others used lower doses.(40) Argatroban is highly protein bound so it is not cleared significantly during hemodialysis. The American College of Chest Physicians guidelines for treatment and prevention of HIT 2012 suggested the use of Argatroban over other non-heparin anticoagulants in HD patients with HITTs.(38) In a research that compared 3 doses of Argatroban in HD patients, the preferred regimen was a 250-µg/kg bolus followed by an infusion of 2 µg/kg/minute at the start of dialysis, with the option of stopping the infusion as early as 1 hour before the end of hemodialysis.(41) Danaparoid…

    • 378 Words
    • 2 Pages
    Decent Essays
  • Decent Essays

    Professor Elwood believes that taking a low-dose of aspirin with other cancer treatment can reduce cancer. The only concerned is if taking a low-dose of aspirin a doctor must check if there is no bleeding or intestinal bleeding. Patients with bowel, breast or prostate cancer have a 15-20% chance at living and cure some of the cancer. As Elwood's team tries to support their evidence on how low-dose of aspirin with cancer treatment. Can stop cancer from spreading and reduce some of the cancer.…

    • 172 Words
    • 1 Pages
    Decent Essays
  • Improved Essays

    The national patient safety goal chosen for this assignment is to “reduce the likelihood of patient harm associated with the use of anticoagulant therapy.” This goal is listed in the Joint Commission’s 2017 Hospital National Patient Safety Goals. To find the guidelines associated with this endeavor searches were completed in CINAHL, Medline, and the National Guideline Clearninghouse using the search terms guideline, guidelines, clinical practice guidelines, anticoagulation, and safety. Furthermore, the results were narrowed to information published in the past decade. The most applicable results are found in the National Guideline Clearninghouse database.…

    • 211 Words
    • 1 Pages
    Improved Essays
  • Decent Essays

    Eribulin mesylate (Halaven, Eisai), an FDA approved drug for use in late stage breast cancer is now concurrently indicated for the treatment of soft-tissue sarcoma (STS) that is inoperable or has metastasized known as liposarcoma. Eribulin mesylate can now be used in patients who have previously received anthracycline chemotherapy as treatment for liposarcoma. Liposarcoma is difficult to treat; most patients tend to have resection of malignant cells or curative surgery. Tumor cells are removed during curative surgery but patients with advance disease state where STS has spread and surgery is not usually an option require radiation/chemotherapy. Eribulin mesylate showed clinically significant results for patients who are difficult to treat because they cannot be treated with surgery and have received previous treatment of chemotherapy (anthracycline) or the cancer has spread to other parts of the body.…

    • 397 Words
    • 2 Pages
    Decent Essays